Back

SGLT2 inhibitors and the risk of atrial fibrillation recurrence within one year after radiofrequency ablation

13 April 2026 (15:30 - 16:15)
Organised by: Logo
Congress Presentation Part of: Risk factor management in atrial fibrillation Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Maria Velescu

Clinical Rehabilitation Hospital Cluj-Napoca, Cluj Napoca (Romania)

5 More presentations in this session

Presentation thumbnail
Association of cognitive impairment with dyslipidemia in patients with atrial fibrillation: preliminary results from a prospective registry
Doctor S. Mohanty (Austin, US)
Abstract Slides Video
Presentation thumbnail
Change in sleep apnea parameters in patients with atrial fibrillation undergoing pulmonary vein isolation: interim analysis of the AAHIi study
Doctor P. Basiukiewicz (Grodzisk Mazowiecki, PL)
Abstract Slides Video
Presentation thumbnail
Improvement in the severity of sleep disordered breathing three months after pulmonary vein isolation in patients with persistent atrial fibrillation
Assistant Professor Y. Naruse (Hamamatsu, JP)
Abstract Slides Video
Presentation thumbnail
Impact of mobile health-detected airflow obstruction on periprocedural symptom severity and quality of life in patients with atrial fibrillation undergoing first-time ablation.
Ms K. Ignaczak (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Optimized concomitant rhythm and ischemia management in patients with atrial fibrillation and coronary artery disease
Doctor J. Dickow (Hamburg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factor management in atrial fibrillation

The Event

Event poster

EHRA 2026

13 April 2026 15:30 CET
You may be interested in
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitors are more effective than dipeptidyl peptidase 4 inhibitors in preventing mid-term recurrence after atrial fibrillation ablation
thumbnail
Congress Presentation
The impact of dapagliflozin on left atrial functions and recurrence in non-diabetic patients in the early post-cryoablation period
thumbnail
Congress Presentation
The impact of dapagliflozin on left atrial functions in non-diabetic atrial fibrillation patients in the early post-cryoablation period

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources